Abstract
Erectile dysfunction (ED) is often associated with cardiovascular disease (CVD) and the risk of sildenafilinduced orthostatic hypotension (OH) in subjects with CVD is a matter of concern. We describe our experience in using the tilt test (TT) with continuous plethysmography to evaluate the occurrence of OH in patients with CVD and ED after a test dose of sildenafil. When sildenafil was added on top of their usual pharmacological treatment two patients out of 32 (6.2%) developed asymptomatic OH, with a maximum blood pressure fall of 40/20 mm Hg. The low prevalence and modest clinical relevance of OH in our high-risk population coupled with the known high sensitivity and reproducibility of the TT seem to suggest that sildenafil is haemodynamically safer than is generally believed even when added on top of vasoactive treatment. These findings should be put into perspective against the growing wealth of evidence that PDE5 inhibitors may have therapeutic potential for a number of CV conditions.
Keywords: Erectile disfunction, sildenafil, orthostatic hypotension, drug safety, cardiovascular disease, Tilt Test, Plethysmography, PDE5 inhibitors
Current Drug Safety
Title: Limited Hypotensive Effect of Sildenafil in a High-Risk Population: A Preliminary Report
Volume: 6 Issue: 4
Author(s): M. M. Ciulla, P. Nicolini, C. Benfenati, C. Vecchiato, G. Acquistapace, G. L. Perrucci and F. Magrini
Affiliation:
Keywords: Erectile disfunction, sildenafil, orthostatic hypotension, drug safety, cardiovascular disease, Tilt Test, Plethysmography, PDE5 inhibitors
Abstract: Erectile dysfunction (ED) is often associated with cardiovascular disease (CVD) and the risk of sildenafilinduced orthostatic hypotension (OH) in subjects with CVD is a matter of concern. We describe our experience in using the tilt test (TT) with continuous plethysmography to evaluate the occurrence of OH in patients with CVD and ED after a test dose of sildenafil. When sildenafil was added on top of their usual pharmacological treatment two patients out of 32 (6.2%) developed asymptomatic OH, with a maximum blood pressure fall of 40/20 mm Hg. The low prevalence and modest clinical relevance of OH in our high-risk population coupled with the known high sensitivity and reproducibility of the TT seem to suggest that sildenafil is haemodynamically safer than is generally believed even when added on top of vasoactive treatment. These findings should be put into perspective against the growing wealth of evidence that PDE5 inhibitors may have therapeutic potential for a number of CV conditions.
Export Options
About this article
Cite this article as:
M. Ciulla M., Nicolini P., Benfenati C., Vecchiato C., Acquistapace G., L. Perrucci G. and Magrini F., Limited Hypotensive Effect of Sildenafil in a High-Risk Population: A Preliminary Report, Current Drug Safety 2011; 6 (4) . https://dx.doi.org/10.2174/157488611798280898
DOI https://dx.doi.org/10.2174/157488611798280898 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nutraceuticals for Promoting Longevity
Current Nutraceuticals Interplay between DNA Methyltransferase 1 and microRNAs During Tumorigenesis
Current Drug Targets Respiratory Failure in Cancer Patients: Non-Infectious Complications of Antineoplastic Agents for Solid Tumors
Current Respiratory Medicine Reviews The Role of Vitamin D in Dyslipidemia and Cardiovascular Disease
Current Pharmaceutical Design Targeting Established Tumor Vasculature: A Novel Approach to Cancer Treatment
Current Cancer Therapy Reviews Antihypertensive Drug Treatment and Circadian Blood Pressure Rhythm: A Review of the Role of Chronotherapy in Hypertension
Current Pharmaceutical Design Possible Therapies of Septic Shock: Based on Animal Studies and Clinical Trials
Current Pharmaceutical Design Cyclic Nucleotides Signaling and Phosphodiesterase Inhibition: Defying Alzheimer’s Disease
Current Drug Targets Late Life Depression: A Diagnostic and Pharmacological Review
Current Psychopharmacology Herb-Drug Interactions: An Insight into Cardiovascular Diseases Based on Case Reports
Cardiovascular & Hematological Agents in Medicinal Chemistry Mitochondrial Biogenesis: Regulation By Endogenous Gases During Inflammation and Organ Stress
Current Pharmaceutical Design The Use of Antiparkinsonian Agents in the Management of Drug-Induced Extrapyramidal Symptoms
Current Pharmaceutical Design Neurokinin-1 (NK<sub>1</sub>) receptor antagonists as possible therapeutics for psychostimulant use disorders
CNS & Neurological Disorders - Drug Targets The Urokinase Receptor System, A Key Regulator at the Intersection between Inflammation, Immunity, and Coagulation
Current Pharmaceutical Design Sepsis Pathophysiology and Anesthetic Consideration
Cardiovascular & Hematological Disorders-Drug Targets Atrial Natriuretic Peptide: Structure, Function, and Physiological Effects: A Narrative Review
Current Cardiology Reviews Highly Active Antiretroviral Therapy and Cardiovascular Complications in HIV-Infected Patients
Current Pharmaceutical Design Neuroprotective Role of Agmatine in Neurological Diseases
Current Neuropharmacology Acute Fulminant Hepatatis in Kidney Transplant Recipient After Repeated Sevoflurane Anesthesia - A Case Report and Literature Review
Current Drug Safety Recent Advances and Future Perspectives of Triazole Analogs as Promising Antiviral Agents
Mini-Reviews in Medicinal Chemistry